Apellis Pharmaceuticals
APLS
APLS
73 hedge funds and large institutions have $639M invested in Apellis Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 4 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
18.13% more ownership
Funds ownership: 33.83% → 51.96% (+18%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
73
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$63.8M | |
| 2 | +$37.2M | |
| 3 | +$22.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1M |
Top Sellers
| 1 | -$23.4M | |
| 2 | -$7.45M | |
| 3 | -$6.51M | |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.66M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$968K |